Modifiable Comorbidities Associated with Cognitive Decline in Parkinson's Disease

Area of Science:

• Neurology
• Neuroscience
• Gerontology

Background:

• Cognitive impairment (CI) is a significant and feared complication of Parkinson's disease (PD).
• Currently, no therapies exist to slow or prevent CI in PD patients.
• Understanding factors influencing CI progression is crucial for developing interventions.

Purpose of the Study:

• To investigate the association between modifiable comorbidities and the rate of cognitive decline in individuals with PD.
• Specific focus on cardiovascular disease risk factors, mood disorders, and sleep characteristics.

Main Methods:

• Utilized data from the Parkinson's Progression Markers Initiative (PPMI) cohort.
• Employed linear mixed-effects models (LME) to analyze baseline factors and cognitive changes over time, measured by the Montreal Cognitive Assessment (MoCA).
• Assessed associations between baseline comorbidities and specific cognitive domains.

Main Results:

• Higher Body Mass Index (BMI), anxiety (STAI), depression (GDS), daytime sleepiness (ESS), and possible REM Sleep Behavior Disorder (RBDSQ) were significantly associated with faster MoCA decline.
• Overweight status, depression, excessive daytime sleepiness, and possible REM sleep behavior disorder correlated with accelerated cognitive decline.

Conclusions:

• Identified several modifiable baseline comorbidities linked to accelerated cognitive decline in Parkinson's disease.
• These findings highlight potential targets for early intervention to manage or slow CI in PD.
• Further research into these modifiable factors could lead to novel therapeutic strategies.